These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23899349)

  • 1. Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.
    Bach P; Antonsson T; Bylund R; Björkman JA; Österlund K; Giordanetto F; van Giezen JJ; Andersen SM; Zachrisson H; Zetterberg F
    J Med Chem; 2013 Sep; 56(17):7015-24. PubMed ID: 23899349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of P2Y
    Kong D; Xue T; Guo B; Cheng J; Liu S; Wei J; Lu Z; Liu H; Gong G; Lan T; Hu W; Yang Y
    J Med Chem; 2019 Mar; 62(6):3088-3106. PubMed ID: 30843696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
    van Giezen JJ; Berntsson P; Zachrisson H; Björkman JA
    Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of ketone-based P2Y(12) receptor antagonists as antithrombotic agents: pharmacodynamics and receptor kinetics considerations.
    Giordanetto F; Bach P; Zetterberg F; Antonsson T; Bylund R; Johansson J; Sellén M; Brown D; Hideståhl L; Berntsson P; Hovdal D; Zachrisson H; Björkman JA; van Giezen JJ
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2963-8. PubMed ID: 24835983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
    Cattaneo M
    Thromb Haemost; 2011 May; 105 Suppl 1():S67-74. PubMed ID: 21479342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.
    Boldron C; Besse A; Bordes MF; Tissandié S; Yvon X; Gau B; Badorc A; Rousseaux T; Barré G; Meneyrol J; Zech G; Nazare M; Fossey V; Pflieger AM; Bonnet-Lignon S; Millet L; Briot C; Dol F; Hérault JP; Savi P; Lassalle G; Delesque N; Herbert JM; Bono F
    J Med Chem; 2014 Sep; 57(17):7293-316. PubMed ID: 25075638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
    Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
    Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.
    Egbertson MS; Cook JJ; Bednar B; Prugh JD; Bednar RA; Gaul SL; Gould RJ; Hartman GD; Homnick CF; Holahan MA; Libby LA; Lynch JJ; Lynch RJ; Sitko GR; Stranieri MT; Vassallo LM
    J Med Chem; 1999 Jul; 42(13):2409-21. PubMed ID: 10395482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
    Zhang S; Hu L; Du H; Guo Y; Zhang Y; Niu H; Jin J; Zhang J; Liu J; Zhang X; Kunapuli SP; Ding Z
    Thromb Haemost; 2010 Oct; 104(4):845-57. PubMed ID: 20806121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
    Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Harris PK; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1388-94. PubMed ID: 20097563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in platelet blockers: the target is the P2Y12 receptor.
    Patel PA; Lane B; Augoustides JG
    J Cardiothorac Vasc Anesth; 2013 Jun; 27(3):620-4. PubMed ID: 23672863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the human P2Y₁₂ receptor in complex with an antithrombotic drug.
    Du B; Liu M
    Sci China Life Sci; 2014 Jun; 57(6):645-6. PubMed ID: 24801571
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
    Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
    J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of the human P2Y12 receptor in complex with an antithrombotic drug.
    Zhang K; Zhang J; Gao ZG; Zhang D; Zhu L; Han GW; Moss SM; Paoletta S; Kiselev E; Lu W; Fenalti G; Zhang W; Müller CE; Yang H; Jiang H; Cherezov V; Katritch V; Jacobson KA; Stevens RC; Wu B; Zhao Q
    Nature; 2014 May; 509(7498):115-8. PubMed ID: 24670650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding.
    André P; DeGuzman F; Haberstock-Debic H; Mills S; Pak Y; Inagaki M; Pandey A; Hollenbach S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Jul; 338(1):22-30. PubMed ID: 21447613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The platelet P2 receptors in arterial thrombosis.
    Gachet C; Léon C; Hechler B
    Blood Cells Mol Dis; 2006; 36(2):223-7. PubMed ID: 16466948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
    Tan GM; Lam YY; Yan BP
    Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
    Frelinger AL; Michelson AD; Wiviott SD; Trenk D; Neumann FJ; Miller DL; Jakubowski JA; Costigan TM; McCabe CH; Antman EM; Braunwald E
    Thromb Haemost; 2011 Aug; 106(2):219-26. PubMed ID: 21713327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.